Core Viewpoint - Oncolytic viruses (OV) represent a promising therapy for cancer treatment, selectively replicating in tumor cells to trigger anti-tumor responses, but systemic delivery remains a challenge due to pre-existing neutralizing antibodies and potential systemic toxicity [3][4]. Group 1 - The research team from Zhejiang University developed a systemically injectable oncolytic virus delivery platform called iNV-GOV, which protects viral particles from immune recognition and directs them to tumor sites, accelerating cancer cell pyroptosis and eliciting a strong anti-tumor immune response [4][5]. - The iNV-GOV platform integrates cancer virotherapy, cell membrane coating technology, CAR targeting, and controlled cell pyroptosis, addressing issues of low viral delivery efficiency and safety while significantly enhancing anti-tumor immune effects [5][7]. Group 2 - The engineered immune-compatible cell membrane expresses chimeric antigen receptors (CAR) to construct the tumor-targeting oncolytic virus delivery platform, functioning as an "invisibility cloak" to protect viral particles and as a "navigation" system to guide them to tumor sites [7]. - The viral load is controlled by a heat shock promoter, allowing ultrasound-induced mild hyperthermia to trigger tumor-specific cell pyroptosis, enhancing tumor lysis and promoting rapid release of oncolytic viruses from lysed tumor cells, thereby increasing infection of adjacent tumor cell populations [7][9]. Group 3 - Overall, this systemically injectable, tumor-targeting oncolytic virus platform enables rapid and sustained proliferation of viruses within tumors, providing a promising new strategy for treating various cancers [9].